+

WO1998009623A2 - Procede de traitement - Google Patents

Procede de traitement Download PDF

Info

Publication number
WO1998009623A2
WO1998009623A2 PCT/GB1997/002349 GB9702349W WO9809623A2 WO 1998009623 A2 WO1998009623 A2 WO 1998009623A2 GB 9702349 W GB9702349 W GB 9702349W WO 9809623 A2 WO9809623 A2 WO 9809623A2
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
medicament
syndrome
patients
multiple sclerosis
Prior art date
Application number
PCT/GB1997/002349
Other languages
English (en)
Other versions
WO1998009623A3 (fr
Inventor
Birgitta Brunes
Christian Brunes
Original Assignee
Scotia Holdings Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scotia Holdings Plc filed Critical Scotia Holdings Plc
Priority to AU40270/97A priority Critical patent/AU4027097A/en
Publication of WO1998009623A2 publication Critical patent/WO1998009623A2/fr
Publication of WO1998009623A3 publication Critical patent/WO1998009623A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin

Definitions

  • the invention relates to drug treatments.
  • Chohnergic drugs are compounds which enhance or imitate the actions of acetyl choline, a natural transmitter in the central and peripheral nervous systems.
  • Drugs which enhance the actions of acetyl choline do so by reducing its rate of inactivation, usually by inhibiting the actions of enzymes known as cholinesterases which normally break down acetyl choline very rapidly.
  • cholinesterases enzymes known as cholinesterases which normally break down acetyl choline very rapidly.
  • anti-cholinesterases and related drugs may thus enhance many of the actions of acetyl choline. Examples are physostigmine, neostigmine. edrophonium, pyridostigmine, demacarium and ambeconium.
  • nicotinic Drugs which imitate the actions of acetyl choline tend to fall into two main classes, nicotinic and muscarinic. These classes arise because there are two major classes of receptors which can both be activated by acetyl-choline. One class can also be readily activated by the alkaloid muscarine and so is called muscarinic, while the other class can readily be activated by nicotine and so is called nicotinic. Examples of cholinergic drugs which can imitate some or all of the actions of acetyl choline are methacholine chloride, carbachol chloride, bethanechol chloride, nicotine, pilocarpine, muscarine and arecoline.
  • the invention therefore lies broadly in the use of such drugs in the treatment of conditions showing these signs and symptoms as set out in the claims herein.
  • Bladder disturbances largely related to inadequate bladder tone. As a result the bladder may not empty fully leading to urinary retention, a frequent sense of need to urinate (urgency), urinary infections, and difficulty in starting urination.
  • Patients may often be relatively slim in relation to their levels of activity and food intake.
  • Tinnitus and sterile prostatitis may also be treated even in patients without multiple sclerosis, depression or the other conditions primarily discussed herein.
  • the syndrome is not due to the administration of anticholinergic drugs, and some features of it, such as the tinnitus, sterile prostatitis and sensory experiences do not appear to have been described in connection with the administration of anticholinergic drugs.
  • the syndrome can occur in individuals who have no other known illness but it is much more likely to be present for example in those who have multiple sclerosis or who are depressed.
  • antidepressants In such patients it may be exacerbated by the administration of antidepressants and by the administration of precursors of adrenergic and serotoninergic transmitters such as L- phenylalanine, L-tyrosine, L-DOPA and L-tryptophan.
  • Any type of antidepressant may precipitate or exaggerate the syndrome, including tricyclic and tetracyclic compounds, selective and non-selective monoamine oxidase inhibitors and the selective serotonin reuptake inhibitors.
  • cholinergic drugs compounds which imitate acetyl choline or which reduce its inactivation.
  • compounds which have combined muscarinic and nicotinic actions or predominantly nicotinic effects are specially effective, although relatively pure muscarinic drugs may have effects on some symptoms.
  • carbachol is the preferred drug although nicotine from smoking or from nicotine patches may also be effective.
  • drugs which may be used for some or all of the symptoms include any drug which exerts agonist effects at muscarinic or nicotinic receptors, such as carbachol, bethanechol, methacholine, any other choline esters, lobeline, pilocarpine. arecoline, cisapride. or any drug which enhances cholinergic activity by inhibiting cholinesterase, such as neostigmine, physostigmine, edrophonium and tacrine.
  • the drugs may be administered by appropriate routes and in appropriate doses, according to the nature of the drug as will be known to those skilled in the art.
  • the routes include oral, sub-cutaneous, other parenteral, topical and ocular routes although in most situations the oral, sub-cutaneous or topical routes are to be preferred.
  • carbachol may be administered in doses of 0.1 - 10 mg orally or sub-cutaneously several times a day as required with a maximum dose in the 30 - 100 mg per day range.
  • slow release formulations or novel derivatives of drugs which act on nicotinic and muscarinic receptors may be developed and such may be used in the present context. More highly lipophilic drugs which more readily penetrate the brain may be of particular value.
  • Nicotine tablets or nicotine gum each unit containing 4mg nicotine.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un médicament pouvant être utilisé pour traiter un syndrome observé dans de multiples scléroses, dépressions ou autres pathologies, mais aussi dans l'acouphène et la prostatite stérile non associés auxdites pathologies. Le médicament comprend une substance cholinergique qui active des récepteurs de choline d'acétyle ou inhibent la dégradation de la choline d'acétyle.
PCT/GB1997/002349 1996-09-03 1997-09-01 Procede de traitement WO1998009623A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU40270/97A AU4027097A (en) 1996-09-03 1997-09-01 Method of treatment

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9618341.3A GB9618341D0 (en) 1996-09-03 1996-09-03 Method of treatment
GB9618341.3 1996-09-03

Publications (2)

Publication Number Publication Date
WO1998009623A2 true WO1998009623A2 (fr) 1998-03-12
WO1998009623A3 WO1998009623A3 (fr) 1998-08-27

Family

ID=10799318

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1997/002349 WO1998009623A2 (fr) 1996-09-03 1997-09-01 Procede de traitement

Country Status (4)

Country Link
AU (1) AU4027097A (fr)
GB (1) GB9618341D0 (fr)
WO (1) WO1998009623A2 (fr)
ZA (1) ZA977867B (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000072835A2 (fr) 1999-05-27 2000-12-07 El Khoury George F Application topique d'agents muscariniques et opioides conçus pour traiter les bourdonnements d'oreilles
WO2001026623A3 (fr) * 1999-10-12 2001-06-21 Laxdale Ltd Traitement de la fatigue, des traumatismes craniens et des accidents vasculaires cerebraux
EP1190709A1 (fr) * 2000-09-21 2002-03-27 Tinnitus Forschungs- und Entwicklungs GmbH Traitement du tintement d'oreille
US7470690B2 (en) 2002-07-10 2008-12-30 Dynogen Pharmaceuticals, Inc. 4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D)pyrimidine in the treatment of functional bowel disorder
WO2011058366A1 (fr) * 2009-11-12 2011-05-19 Acacia Pharma Limited Utilisation de béthanécol pour le traitement de la xérostomie
WO2012153110A1 (fr) * 2011-05-06 2012-11-15 Acacia Pharma Limited Utilisation de béthanechol pour le traitement de la xérostomie

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4857534A (en) * 1984-04-05 1989-08-15 North Carolina State University Method of maintaining ruminants on high energy low fiber diet
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
EP0659077A1 (fr) * 1992-07-02 1995-06-28 TheraTech, Inc. Systeme d'administration de la pilocarpine a liberation controlee
JP2852608B2 (ja) * 1994-06-27 1999-02-03 雪印乳業株式会社 口腔乾燥症治療剤

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000072835A2 (fr) 1999-05-27 2000-12-07 El Khoury George F Application topique d'agents muscariniques et opioides conçus pour traiter les bourdonnements d'oreilles
WO2000072835A3 (fr) * 1999-05-27 2002-03-21 Khoury George F El Application topique d'agents muscariniques et opioides conçus pour traiter les bourdonnements d'oreilles
US6465442B2 (en) 1999-05-27 2002-10-15 George F. El Khoury Topical application of muscarinic and opioid agents for treatment of tinnitus
WO2001026623A3 (fr) * 1999-10-12 2001-06-21 Laxdale Ltd Traitement de la fatigue, des traumatismes craniens et des accidents vasculaires cerebraux
EP1190709A1 (fr) * 2000-09-21 2002-03-27 Tinnitus Forschungs- und Entwicklungs GmbH Traitement du tintement d'oreille
WO2002024176A3 (fr) * 2000-09-21 2003-05-22 Tinnitus Forschungs Und Entwic Traitement de l'acouphene
EP1559420A1 (fr) * 2000-09-21 2005-08-03 Tinnitus Forschungs- und Entwicklungs GmbH Traitement de l'acouphéne
US7470690B2 (en) 2002-07-10 2008-12-30 Dynogen Pharmaceuticals, Inc. 4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D)pyrimidine in the treatment of functional bowel disorder
WO2011058366A1 (fr) * 2009-11-12 2011-05-19 Acacia Pharma Limited Utilisation de béthanécol pour le traitement de la xérostomie
CN102711752A (zh) * 2009-11-12 2012-10-03 阿卡西亚制药有限公司 氨甲酰甲胆碱用于治疗口干燥症的用途
AU2010317747B2 (en) * 2009-11-12 2013-10-17 Acacia Pharma Limited Use of bethanechol for treatment of xerostomia
CN102711752B (zh) * 2009-11-12 2014-06-18 阿卡西亚制药有限公司 氨甲酰甲胆碱用于治疗口干燥症的用途
US9149454B2 (en) 2009-11-12 2015-10-06 Acacia Pharma Limited Use of bethanechol for treatment of xerostomia
EA022040B1 (ru) * 2009-11-12 2015-10-30 Экейше Фарма Лимитед Применение бетанехола для лечения ксеростомии
US10137084B2 (en) 2009-11-12 2018-11-27 Acacia Pharma Limited Use of bethanechol for treatment of xerostomia
WO2012153110A1 (fr) * 2011-05-06 2012-11-15 Acacia Pharma Limited Utilisation de béthanechol pour le traitement de la xérostomie
US9492546B2 (en) 2011-05-06 2016-11-15 Acacia Pharma Limited Use of bethanechol for treatment of Xerostomia

Also Published As

Publication number Publication date
ZA977867B (en) 1998-05-27
AU4027097A (en) 1998-03-26
GB9618341D0 (en) 1996-10-16
WO1998009623A3 (fr) 1998-08-27

Similar Documents

Publication Publication Date Title
AU710339B2 (en) Treatment of multiple sclerosis (ms) and other demyelinating conditions using lofepramine in combination with l-phenylalanine, tyrosine or tryptophan and possibly a vitamin b12 compound
Jasinski et al. Clonidine in morphine withdrawal: differential effects on signs and symptoms
Walling Amyotrophic lateral sclerosis: Lou Gehrig's disease
Ciraulo et al. Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics
RU2281771C2 (ru) Использование декстрометорфана и ингибитора оксидазы для отучения пациентов от наркотиков и антидепрессантов
Mawdsley Treatment of Parkinsonism with Laevo-dopa
Smith Cocaine-alcohol abuse: Epidemiological, diagnostic and treatment considerations
Shimm et al. Medical management of chronic cancer pain
HUP0400865A2 (hu) Hatóanyag-kombinációt tartalmazó készítmények szenvedély- vagy kábítószer-betegségek kezelésére és eljárás a készítmények előállítására
WO1998009623A2 (fr) Procede de traitement
Ng et al. Venlafaxine and bilateral acute angle closure glaucoma
KR100692235B1 (ko) 안지오텐신 ⅱ 길항물질의 신규한 용도
MacDiarmid Maximizing anticholinergic therapy for overactive bladder: has the ceiling been reached?
ZA200404053B (en) Use of desoxypeganine for treating clinical depression.
EP4419091A1 (fr) Traitement de l'irritabilité chez des sujets atteints de troubles du spectre autistique avec une anxiété modérée à grave et/ou un évitement social
Denis et al. Bilateral acute angle-closure glaucoma after dexfenfluramine treatment
Rappolt et al. Use of Inderal (propranolol-Ayerst) in Ia (early stimulative) and Ib (advanced stimulative) classification of cocaine and other sympathomimetic reactions
JPH06509073A (ja) 光学的に純粋なｓ（−）オンダンセトロンを使用する嘔吐、吐き気および他の障害の治療のための方法および組成物
AU2005308258B2 (en) Therapeutic agent for drug dependence
Leopold Trends in Ocular Therapy: The 23rd Sanford S. Gifford Memorial Lecture
JP2593910B2 (ja) パニック障害の予防又は抑制剤
US4098899A (en) Method of reducing psychogenic impotence
Selby Treatment of parkinsonism
Gillman et al. Parkinsonism induced by a monoamine oxidase inhibitor
Joos et al. Autonomic control of the pupil

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998512338

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载